Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Primary Purpose
Restrictive Burn Scars of Joint Area
Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Autologous Human Fibroblasts (Isolagen TherapyTM)
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Restrictive Burn Scars of Joint Area
Eligibility Criteria
Inclusion Criteria:
- Subject is at least 18 years of age
- Subject has "stable" restrictive burn scar of a jointed area that restricts range of motion (ROM) of the affected joint by greater than or equal to 20% and that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction)
- Subject agrees to maintain any current physical therapy regimen for the duration of the study
- Subject must be able to provide written informed consent and comply with the study requirements
- Females of childbearing potential must have a negative urine pregnancy test at the screening visit and must agree to use a reliable means of birth control for the duration of the study
- Male subjects must agree to use a reliable means of birth control for the duration of the study
- Subject has healthy, non-scarred post auricular, abdomen, back of neck at hairline, lower abdomen, upper arm, side of upper leg, or axillary region (on the lateral thorax) skin area suitable for biopsy
- Subject has normal CBC, thyroid function, renal function, liver function, blood glucose and SMA 18 at Screening
Exclusion Criteria:
- The restrictive burn scar to be treated is primarily classified as a keloid scar
- Surgical release of scar to be treated within the last 12 months
- Subjects for whom a skin biopsy cannot be collected
- Plans to initiate any new scar therapy during the study period
- Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study
- History of active autoimmune disease or organ transplantation
- Diagnosis of cancer, including basal cell carcinoma, unless successfully treated or in remission for a minimum of 6 months
- Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, epidermolysis bullosa, ataxia-telangiectasia, or Ehlers Danlos syndrome
- Active systemic infection as shown by any one of the following: symptoms, fever and/or an elevated white count (subjects who present with an active systemic infection may be enrolled and biopsied after the infection has resolved)
- Requires chronic antibiotic or steroidal therapy
- Any conditions that are considered by the Investigator to be contraindications to biopsy or injection
- Pregnant or lactating women or women trying to become pregnant during the study
- Subject has any disorder that may prevent compliance, such as history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the Investigator's opinion, interfere with the study
- Presence of other disease or condition that would result in impairment of the range of motion of the extremity, e.g. rheumatoid arthritis or stroke
- Subjects with a known allergy to gentamycin or amphotericin B, or sensitivity to materials of bovine origin
Sites / Locations
- Brigham and Women's Hospital
- Nassau County Medical Center
- University of Texas Medical Branch- Galveston
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Active Arm
Control Arm
Arm Description
Active Treatment
Placebo treatment
Outcomes
Primary Outcome Measures
Change from baseline of all study assessments
Secondary Outcome Measures
Review of adverse Events, vital signs and physical examination
Full Information
NCT ID
NCT00620737
First Posted
February 11, 2008
Last Updated
February 8, 2012
Sponsor
Castle Creek Biosciences, LLC.
1. Study Identification
Unique Protocol Identification Number
NCT00620737
Brief Title
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Withdrawn
Why Stopped
Company Decision
Study Start Date
February 2008 (undefined)
Primary Completion Date
December 2008 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Castle Creek Biosciences, LLC.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM and placebo when administered to stable restrictive burn scars of an affected joint area.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Restrictive Burn Scars of Joint Area
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active Arm
Arm Type
Experimental
Arm Description
Active Treatment
Arm Title
Control Arm
Arm Type
Placebo Comparator
Arm Description
Placebo treatment
Intervention Type
Biological
Intervention Name(s)
Autologous Human Fibroblasts (Isolagen TherapyTM)
Intervention Description
Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits
Primary Outcome Measure Information:
Title
Change from baseline of all study assessments
Time Frame
Day 0, 14, 30, 60, 90 and 120
Secondary Outcome Measure Information:
Title
Review of adverse Events, vital signs and physical examination
Time Frame
Day 0, 14, 30, 60, 90 and 120
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject is at least 18 years of age
Subject has "stable" restrictive burn scar of a jointed area that restricts range of motion (ROM) of the affected joint by greater than or equal to 20% and that is no deeper than the fascia (i.e., underlying structures including ligament, tendon, muscle, and bone must not contribute to the restriction)
Subject agrees to maintain any current physical therapy regimen for the duration of the study
Subject must be able to provide written informed consent and comply with the study requirements
Females of childbearing potential must have a negative urine pregnancy test at the screening visit and must agree to use a reliable means of birth control for the duration of the study
Male subjects must agree to use a reliable means of birth control for the duration of the study
Subject has healthy, non-scarred post auricular, abdomen, back of neck at hairline, lower abdomen, upper arm, side of upper leg, or axillary region (on the lateral thorax) skin area suitable for biopsy
Subject has normal CBC, thyroid function, renal function, liver function, blood glucose and SMA 18 at Screening
Exclusion Criteria:
The restrictive burn scar to be treated is primarily classified as a keloid scar
Surgical release of scar to be treated within the last 12 months
Subjects for whom a skin biopsy cannot be collected
Plans to initiate any new scar therapy during the study period
Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study
History of active autoimmune disease or organ transplantation
Diagnosis of cancer, including basal cell carcinoma, unless successfully treated or in remission for a minimum of 6 months
Known genetic disorders affecting fibroblasts or collagen, such as achondroplasia, osteogenesis imperfecta, epidermolysis bullosa, ataxia-telangiectasia, or Ehlers Danlos syndrome
Active systemic infection as shown by any one of the following: symptoms, fever and/or an elevated white count (subjects who present with an active systemic infection may be enrolled and biopsied after the infection has resolved)
Requires chronic antibiotic or steroidal therapy
Any conditions that are considered by the Investigator to be contraindications to biopsy or injection
Pregnant or lactating women or women trying to become pregnant during the study
Subject has any disorder that may prevent compliance, such as history of chronic alcohol or drug abuse, significant mental or nervous disorder or other illness that would, in the Investigator's opinion, interfere with the study
Presence of other disease or condition that would result in impairment of the range of motion of the extremity, e.g. rheumatoid arthritis or stroke
Subjects with a known allergy to gentamycin or amphotericin B, or sensitivity to materials of bovine origin
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Nassau County Medical Center
City
East Meadow
State/Province
New York
ZIP/Postal Code
11554
Country
United States
Facility Name
University of Texas Medical Branch- Galveston
City
Galveston
State/Province
Texas
ZIP/Postal Code
77555
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
We'll reach out to this number within 24 hrs